Latest News & Updates
James P. Allison, PhD, was honored in the Scientific Advances category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.
Patients with metastatic colorectal cancer benefited from treatment with cetuximab plus chemotherapy even after disease progression on a similar regimen as long as their tumors did not harbor mutations in any of four key genes.
The survival benefit observed with regorafenib (Stivarga) over placebo in Asian patients who had been previously treated for metastatic colorectal cancer in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.
Findings from a large expanded access program have confirmed the efficacy and safety of regorafenib in patients with previously treated metastatic colorectal cancer.
TAS-102 demonstrated similar improvements in overall survival and progression-free survival in patients with heavily pretreated colorectal cancer from the phase III RECOURSE trial stratified by KRAS mutational status.
Latest Peer Exchange Discussions
Robert L. Coleman, MD, reviews the approval of bevacizumab in women with platinum-resistant ovarian cancer. View Now
F. Anthony Greco, MD, and Suresh S. Ramalingam, MD, explain the utilities of different genomic tests, such as CancerTYPE ID and CancerTREATMENT NGS+. View Now
Bradley J. Monk, MD, and Angeles Alvarez Secord, MD, explain histological subtypes and gene mutations found in ovarian cancer. View Now
Most Popular Right Now
Online CME Activities